Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.

Hsieh YY, Chang CC, Tsai HD

Taiwanese journal of obstetrics & gynecology1 Mar 2008Cited by 28 (Europe PMC)

PMID18400585DOI10.1016/s1028-4559(08)60057-1PepBankPUB-18400585

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study47

47 results from studies that gave the peptide. 47 results from people.

01HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.25 mg, LH surge risk was 3.5%.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.25 mg, LH surge risk was 3.5%.
Peptide
Cetrorelix
Outcome
Not applicableLH surge risk
Study
n = 86
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
LH surge risk
3.5%
cetrorelix 0.25 mg
Source sentences
Summary
LH/OHSS risks were: (1) 3.5%/5.8%; (2) 7.1%/3.6%; (3) 13.3%/3.3%; (4) 3.4%/8.6%; and (5) 2%/8.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058507
02HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.25 mg, oocyte number was 9.4.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.25 mg, egg number was 9.4.
Peptide
Cetrorelix
Outcome
Not applicableOocyte number
Study
n = 86
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Number of oocytes
9.4 count
cetrorelix 0.25 mg
Source sentences
Summary
Number of oocytes/embryos/grade I, II embryos were: (1) 9.4/7.9/5.8; (2) 7.5/4.2/3.6; (3) 6.3/4.1/3.1; (4) 12.3/8.9/6.6; and (5) 11.8/8.4/6.1, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058513
03HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.25 mg, embryo number was 7.9.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.25 mg, embryo number was 7.9.
Peptide
Cetrorelix
Outcome
Not applicableEmbryo number
Study
n = 86
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Number of embryos
7.9 count
cetrorelix 0.25 mg
Source sentences
Summary
Number of oocytes/embryos/grade I, II embryos were: (1) 9.4/7.9/5.8; (2) 7.5/4.2/3.6; (3) 6.3/4.1/3.1; (4) 12.3/8.9/6.6; and (5) 11.8/8.4/6.1, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058516
04HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.25 mg, grade I and II embryo number was 5.8.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.25 mg, grade I and II embryo number was 5.8.
Peptide
Cetrorelix
Outcome
Not applicableGrade I and II embryo number
Study
n = 86
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Number of grade I, II embryos
5.8 count
cetrorelix 0.25 mg
Source sentences
Summary
Number of oocytes/embryos/grade I, II embryos were: (1) 9.4/7.9/5.8; (2) 7.5/4.2/3.6; (3) 6.3/4.1/3.1; (4) 12.3/8.9/6.6; and (5) 11.8/8.4/6.1, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058519
05HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.25 mg, chemical pregnancy rate was 30.2%.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.25 mg, chemical pregnancy rate was 30.2%.
Peptide
Cetrorelix
Outcome
Not applicableChemical pregnancy rate
Study
n = 86
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Chemical pregnancy rate
30.2%
cetrorelix 0.25 mg
Source sentences
Summary
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058522
06HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.25 mg, implantation rate was 5.9%.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.25 mg, implantation rate was 5.9%.
Peptide
Cetrorelix
Outcome
Not applicableImplantation rate
Study
n = 86
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Implantation rate
5.9%
cetrorelix 0.25 mg
Source sentences
Summary
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058525
07HumanNon-randomized trialSafety outcome
In IVF/ICSI patients receiving cetrorelix 0.25 mg, abortion rate was 7%.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.25 mg, abortion rate was 7%.
Peptide
Cetrorelix
Outcome
Not applicableAbortion rate
Study
n = 86
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Abortion rate
7%
cetrorelix 0.25 mg
Source sentences
Summary
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058528
08HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, the abstract reports a higher risk of LH surge in the cetrorelix 0.15 mg group (13.3%), without naming the comparison group.
In plain wordsIn IVF/ICSI patients, LH surge was reported as more likely with cetrorelix 0.15 mg (13.3%); the abstract does not name the comparison group.
Peptide
Cetrorelix
Outcome
IncreaseLH surge risk
Study
n = 30
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
LH surge risk
13.3%
cetrorelix 0.15 mg
Source sentences
Summary
A higher risk of luteinizing hormone (LH) surge was noted in cetrorelix 0.2 and 0.15 mg groups.
3 context sentences(design, population, supporting numbers)
Summary · context
LH/OHSS risks were: (1) 3.5%/5.8%; (2) 7.1%/3.6%; (3) 13.3%/3.3%; (4) 3.4%/8.6%; and (5) 2%/8.2%, respectively.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058509
09HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.15 mg, oocyte number was 6.3.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.15 mg, egg number was 6.3.
Peptide
Cetrorelix
Outcome
Not applicableOocyte number
Study
n = 30
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Number of oocytes
6.3 count
cetrorelix 0.15 mg
Source sentences
Summary
Number of oocytes/embryos/grade I, II embryos were: (1) 9.4/7.9/5.8; (2) 7.5/4.2/3.6; (3) 6.3/4.1/3.1; (4) 12.3/8.9/6.6; and (5) 11.8/8.4/6.1, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058515
10HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.15 mg, embryo number was 4.1.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.15 mg, embryo number was 4.1.
Peptide
Cetrorelix
Outcome
Not applicableEmbryo number
Study
n = 30
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Number of embryos
4.1 count
cetrorelix 0.15 mg
Source sentences
Summary
Number of oocytes/embryos/grade I, II embryos were: (1) 9.4/7.9/5.8; (2) 7.5/4.2/3.6; (3) 6.3/4.1/3.1; (4) 12.3/8.9/6.6; and (5) 11.8/8.4/6.1, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058518
11HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.15 mg, grade I and II embryo number was 3.1.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.15 mg, grade I and II embryo number was 3.1.
Peptide
Cetrorelix
Outcome
Not applicableGrade I and II embryo number
Study
n = 30
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Number of grade I, II embryos
3.1 count
cetrorelix 0.15 mg
Source sentences
Summary
Number of oocytes/embryos/grade I, II embryos were: (1) 9.4/7.9/5.8; (2) 7.5/4.2/3.6; (3) 6.3/4.1/3.1; (4) 12.3/8.9/6.6; and (5) 11.8/8.4/6.1, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058521
12HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.15 mg, chemical pregnancy rate was 16.7%.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.15 mg, chemical pregnancy rate was 16.7%.
Peptide
Cetrorelix
Outcome
Not applicableChemical pregnancy rate
Study
n = 30
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Chemical pregnancy rate
16.7%
cetrorelix 0.15 mg
Source sentences
Summary
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058524
13HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.15 mg, implantation rate was 4.1%.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.15 mg, implantation rate was 4.1%.
Peptide
Cetrorelix
Outcome
Not applicableImplantation rate
Study
n = 30
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Implantation rate
4.1%
cetrorelix 0.15 mg
Source sentences
Summary
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058527
14HumanNon-randomized trialSafety outcome
In IVF/ICSI patients receiving cetrorelix 0.15 mg, abortion rate was 10%.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.15 mg, abortion rate was 10%.
Peptide
Cetrorelix
Outcome
Not applicableAbortion rate
Study
n = 30
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Abortion rate
10%
cetrorelix 0.15 mg
Source sentences
Summary
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058530
15HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, the abstract reports a higher risk of LH surge in the cetrorelix 0.2 mg group (7.1%), without naming the comparison group.
In plain wordsIn IVF/ICSI patients, LH surge was reported as more likely with cetrorelix 0.2 mg (7.1%); the abstract does not name the comparison group.
Peptide
Cetrorelix
Outcome
IncreaseLH surge risk
Study
n = 28
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
LH surge risk
7.1%
cetrorelix 0.2 mg
Source sentences
Summary
A higher risk of luteinizing hormone (LH) surge was noted in cetrorelix 0.2 and 0.15 mg groups.
3 context sentences(design, population, supporting numbers)
Summary · context
LH/OHSS risks were: (1) 3.5%/5.8%; (2) 7.1%/3.6%; (3) 13.3%/3.3%; (4) 3.4%/8.6%; and (5) 2%/8.2%, respectively.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058508
16HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.2 mg, oocyte number was 7.5.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.2 mg, egg number was 7.5.
Peptide
Cetrorelix
Outcome
Not applicableOocyte number
Study
n = 28
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Number of oocytes
7.5 count
cetrorelix 0.2 mg
Source sentences
Summary
Number of oocytes/embryos/grade I, II embryos were: (1) 9.4/7.9/5.8; (2) 7.5/4.2/3.6; (3) 6.3/4.1/3.1; (4) 12.3/8.9/6.6; and (5) 11.8/8.4/6.1, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058514
17HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.2 mg, embryo number was 4.2.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.2 mg, embryo number was 4.2.
Peptide
Cetrorelix
Outcome
Not applicableEmbryo number
Study
n = 28
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Number of embryos
4.2 count
cetrorelix 0.2 mg
Source sentences
Summary
Number of oocytes/embryos/grade I, II embryos were: (1) 9.4/7.9/5.8; (2) 7.5/4.2/3.6; (3) 6.3/4.1/3.1; (4) 12.3/8.9/6.6; and (5) 11.8/8.4/6.1, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058517
18HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.2 mg, grade I and II embryo number was 3.6.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.2 mg, grade I and II embryo number was 3.6.
Peptide
Cetrorelix
Outcome
Not applicableGrade I and II embryo number
Study
n = 28
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Number of grade I, II embryos
3.6 count
cetrorelix 0.2 mg
Source sentences
Summary
Number of oocytes/embryos/grade I, II embryos were: (1) 9.4/7.9/5.8; (2) 7.5/4.2/3.6; (3) 6.3/4.1/3.1; (4) 12.3/8.9/6.6; and (5) 11.8/8.4/6.1, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058520
19HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.2 mg, chemical pregnancy rate was 21.4%.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.2 mg, chemical pregnancy rate was 21.4%.
Peptide
Cetrorelix
Outcome
Not applicableChemical pregnancy rate
Study
n = 28
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Chemical pregnancy rate
21.4%
cetrorelix 0.2 mg
Source sentences
Summary
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058523
20HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients receiving cetrorelix 0.2 mg, implantation rate was 5.1%.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.2 mg, implantation rate was 5.1%.
Peptide
Cetrorelix
Outcome
Not applicableImplantation rate
Study
n = 28
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Implantation rate
5.1%
cetrorelix 0.2 mg
Source sentences
Summary
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058526
21HumanNon-randomized trialSafety outcome
In IVF/ICSI patients receiving cetrorelix 0.2 mg, abortion rate was 7.1%.
In plain wordsIn IVF/ICSI patients receiving cetrorelix 0.2 mg, abortion rate was 7.1%.
Peptide
Cetrorelix
Outcome
Not applicableAbortion rate
Study
n = 28
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Abortion rate
7.1%
cetrorelix 0.2 mg
Source sentences
Summary
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058529
22HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.25 mg: 1,949.4 versus 2,184.5 IU with daily leuprolide.
In plain wordsIn IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.25 mg than daily leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseGonadotropin dose
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Gonadotropin dose
1949.4 IU
cetrorelix 0.25 mg
Gonadotropin dose
2184.5 IU
leuprolide acetate 0.5 mg/day
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058501
23HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.2 mg: 1,869.6 versus 2,184.5 IU with daily leuprolide.
In plain wordsIn IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.2 mg than daily leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseGonadotropin dose
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Gonadotropin dose
1869.6 IU
cetrorelix 0.2 mg
Gonadotropin dose
2184.5 IU
leuprolide acetate 0.5 mg/day
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058502
24HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.15 mg: 1,856.7 versus 2,184.5 IU with daily leuprolide.
In plain wordsIn IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.15 mg than daily leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseGonadotropin dose
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Gonadotropin dose
1856.7 IU
cetrorelix 0.15 mg
Gonadotropin dose
2184.5 IU
leuprolide acetate 0.5 mg/day
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058503
25HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, estradiol was lower with cetrorelix 0.25 mg: 1,191.1 versus 1,323.6 pg/mL with daily leuprolide.
In plain wordsIn IVF/ICSI patients, estradiol was lower with cetrorelix 0.25 mg than daily leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseEstradiol
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Estradiol
1191.1 pg/mL
cetrorelix 0.25 mg
Estradiol
1323.6 pg/mL
leuprolide acetate 0.5 mg/day
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058504
26HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, estradiol was lower with cetrorelix 0.2 mg: 1,010.8 versus 1,323.6 pg/mL with daily leuprolide.
In plain wordsIn IVF/ICSI patients, estradiol was lower with cetrorelix 0.2 mg than daily leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseEstradiol
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Estradiol
1010.8 pg/mL
cetrorelix 0.2 mg
Estradiol
1323.6 pg/mL
leuprolide acetate 0.5 mg/day
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058505
27HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, estradiol was lower with cetrorelix 0.15 mg: 1,023.6 versus 1,323.6 pg/mL with daily leuprolide.
In plain wordsIn IVF/ICSI patients, estradiol was lower with cetrorelix 0.15 mg than daily leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseEstradiol
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Estradiol
1023.6 pg/mL
cetrorelix 0.15 mg
Estradiol
1323.6 pg/mL
leuprolide acetate 0.5 mg/day
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058506
28HumanNon-randomized trialSafety outcome
In IVF/ICSI patients, OHSS risk was lower with cetrorelix 0.25 mg: 5.8 versus 8.6 % with daily leuprolide.
In plain wordsIn IVF/ICSI patients, OHSS risk was lower with cetrorelix 0.25 mg than daily leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseOHSS risk
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg/day
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
OHSS risk
5.8%
cetrorelix 0.25 mg
OHSS risk
8.6%
leuprolide acetate 0.5 mg/day
Source sentences
Summary
LH/OHSS risks were: (1) 3.5%/5.8%; (2) 7.1%/3.6%; (3) 13.3%/3.3%; (4) 3.4%/8.6%; and (5) 2%/8.2%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058510
29HumanNon-randomized trialSafety outcome
In IVF/ICSI patients, OHSS risk was lower with cetrorelix 0.2 mg: 3.6 versus 8.6 % with daily leuprolide.
In plain wordsIn IVF/ICSI patients, OHSS risk was lower with cetrorelix 0.2 mg than daily leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseOHSS risk
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg/day
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
OHSS risk
3.6%
cetrorelix 0.2 mg
OHSS risk
8.6%
leuprolide acetate 0.5 mg/day
Source sentences
Summary
LH/OHSS risks were: (1) 3.5%/5.8%; (2) 7.1%/3.6%; (3) 13.3%/3.3%; (4) 3.4%/8.6%; and (5) 2%/8.2%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058511
30HumanNon-randomized trialSafety outcome
In IVF/ICSI patients, OHSS risk was lower with cetrorelix 0.15 mg: 3.3 versus 8.6 % with daily leuprolide.
In plain wordsIn IVF/ICSI patients, OHSS risk was lower with cetrorelix 0.15 mg than daily leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseOHSS risk
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg/day
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
OHSS risk
3.3%
cetrorelix 0.15 mg
OHSS risk
8.6%
leuprolide acetate 0.5 mg/day
Source sentences
Summary
LH/OHSS risks were: (1) 3.5%/5.8%; (2) 7.1%/3.6%; (3) 13.3%/3.3%; (4) 3.4%/8.6%; and (5) 2%/8.2%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058512
31HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, clinical outcomes did not differ significantly between cetrorelix 0.25 mg and daily leuprolide, except abortion rates.
In plain wordsIn IVF/ICSI patients, clinical outcomes were similar with cetrorelix 0.25 mg and daily leuprolide, except abortion rates.
Peptide
Cetrorelix
Outcome
No significant changeClinical outcomes
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg/day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Source sentences
Summary
There was no significant difference in terms of clinical outcomes between groups 1, 4 and 5, except for higher abortion rates (AR) in group 1.
3 context sentences(design, population, supporting numbers)
Summary · context
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058531
32HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, clinical outcomes did not differ significantly between cetrorelix 0.25 mg and depot leuprolide, except abortion rates.
In plain wordsIn IVF/ICSI patients, clinical outcomes were similar with cetrorelix 0.25 mg and depot leuprolide, except abortion rates.
Peptide
Cetrorelix
Outcome
No significant changeClinical outcomes
Study
n: not reported in source
Comparator
Leuprolide acetate depot 1.88 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Source sentences
Summary
There was no significant difference in terms of clinical outcomes between groups 1, 4 and 5, except for higher abortion rates (AR) in group 1.
3 context sentences(design, population, supporting numbers)
Summary · context
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058532
33HumanNon-randomized trialSafety outcome
In IVF/ICSI patients, the abstract reports higher abortion rates with cetrorelix 0.25 mg than daily leuprolide, despite inconsistent numerical rates.
In plain wordsIn IVF/ICSI patients, the abstract reports higher abortion rates with cetrorelix than daily leuprolide, despite inconsistent numerical rates.
Peptide
Cetrorelix
Outcome
IncreaseAbortion rate comparison
Study
n: not reported in source
Comparator
Leuprolide acetate 0.5 mg/day
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Abortion rate
7%
cetrorelix 0.25 mg
Abortion rate
8.6%
leuprolide acetate 0.5 mg/day
Source sentences
Summary
There was no significant difference in terms of clinical outcomes between groups 1, 4 and 5, except for higher abortion rates (AR) in group 1.
3 context sentences(design, population, supporting numbers)
Summary · context
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058533
34HumanNon-randomized trialSafety outcome
In IVF/ICSI patients, the abstract reports higher abortion rates with cetrorelix 0.25 mg than depot leuprolide, despite inconsistent numerical rates.
In plain wordsIn IVF/ICSI patients, the abstract reports higher abortion rates with cetrorelix than depot leuprolide, despite inconsistent numerical rates.
Peptide
Cetrorelix
Outcome
IncreaseAbortion rate comparison
Study
n: not reported in source
Comparator
Leuprolide acetate depot 1.88 mg
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Abortion rate
7%
cetrorelix 0.25 mg
Abortion rate
8.2%
leuprolide acetate depot 1.88 mg
Source sentences
Summary
There was no significant difference in terms of clinical outcomes between groups 1, 4 and 5, except for higher abortion rates (AR) in group 1.
3 context sentences(design, population, supporting numbers)
Summary · context
Chemical PR/IR/AR were: (1) 30.2%/5.9%/7%; (2) 21.4%/5.1%/7.1%; (3) 16.7%/4.1%/10%; (4) 32.8%/5.5%/8.6%; and (5) 30.6%/5.7%/8.2%, respectively.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058534
35HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, pregnancy rate was statistically higher with cetrorelix 0.25 mg than 0.2 mg.
In plain wordsIn IVF/ICSI patients, pregnancy rate was higher with cetrorelix 0.25 mg than 0.2 mg.
Peptide
Cetrorelix
Outcome
IncreasePregnancy rate
Study
n: not reported in source
Comparator
Cetrorelix 0.2 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Source sentences
Summary
Pregnancy rate (PR)/implantation rate (IR) ratios in groups 1, 4, and 5 were statistically higher than those in groups 2 and 3.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058535
36HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, pregnancy rate was statistically higher with cetrorelix 0.25 mg than 0.15 mg.
In plain wordsIn IVF/ICSI patients, pregnancy rate was higher with cetrorelix 0.25 mg than 0.15 mg.
Peptide
Cetrorelix
Outcome
IncreasePregnancy rate
Study
n: not reported in source
Comparator
Cetrorelix 0.15 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Source sentences
Summary
Pregnancy rate (PR)/implantation rate (IR) ratios in groups 1, 4, and 5 were statistically higher than those in groups 2 and 3.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058536
37HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, implantation rate was statistically higher with cetrorelix 0.25 mg than 0.2 mg.
In plain wordsIn IVF/ICSI patients, implantation rate was higher with cetrorelix 0.25 mg than 0.2 mg.
Peptide
Cetrorelix
Outcome
IncreaseImplantation rate comparison
Study
n: not reported in source
Comparator
Cetrorelix 0.2 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Source sentences
Summary
Pregnancy rate (PR)/implantation rate (IR) ratios in groups 1, 4, and 5 were statistically higher than those in groups 2 and 3.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058537
38HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, implantation rate was statistically higher with cetrorelix 0.25 mg than 0.15 mg.
In plain wordsIn IVF/ICSI patients, implantation rate was higher with cetrorelix 0.25 mg than 0.15 mg.
Peptide
Cetrorelix
Outcome
IncreaseImplantation rate comparison
Study
n: not reported in source
Comparator
Cetrorelix 0.15 mg daily
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Source sentences
Summary
Pregnancy rate (PR)/implantation rate (IR) ratios in groups 1, 4, and 5 were statistically higher than those in groups 2 and 3.
2 context sentences(design, population, supporting numbers)
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30);
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058538
39HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.25 mg: 1,949.4 versus 2,103.5 IU with depot leuprolide.
In plain wordsIn IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.25 mg than depot leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseGonadotropin dose
Study
n: not reported in source
Comparator
Leuprolide acetate depot 1.88 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Gonadotropin dose
1949.4 IU
cetrorelix 0.25 mg
Gonadotropin dose
2103.5 IU
single half-dose leuprolide acetate depot 1.88 mg
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058539
40HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.2 mg: 1,869.6 versus 2,103.5 IU with depot leuprolide.
In plain wordsIn IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.2 mg than depot leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseGonadotropin dose
Study
n: not reported in source
Comparator
Leuprolide acetate depot 1.88 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Gonadotropin dose
1869.6 IU
cetrorelix 0.2 mg
Gonadotropin dose
2103.5 IU
single half-dose leuprolide acetate depot 1.88 mg
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058540
41HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.15 mg: 1,856.7 versus 2,103.5 IU with depot leuprolide.
In plain wordsIn IVF/ICSI patients, gonadotropin dose was lower with cetrorelix 0.15 mg than depot leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseGonadotropin dose
Study
n: not reported in source
Comparator
Leuprolide acetate depot 1.88 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Gonadotropin dose
1856.7 IU
cetrorelix 0.15 mg
Gonadotropin dose
2103.5 IU
single half-dose leuprolide acetate depot 1.88 mg
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058541
42HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, estradiol was lower with cetrorelix 0.25 mg: 1,191.1 versus 1,313.5 pg/mL with depot leuprolide.
In plain wordsIn IVF/ICSI patients, estradiol was lower with cetrorelix 0.25 mg than depot leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseEstradiol
Study
n: not reported in source
Comparator
Leuprolide acetate depot 1.88 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Estradiol
1191.1 pg/mL
cetrorelix 0.25 mg
Estradiol
1313.5 pg/mL
single half-dose leuprolide acetate depot 1.88 mg
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058542
43HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, estradiol was lower with cetrorelix 0.2 mg: 1,010.8 versus 1,313.5 pg/mL with depot leuprolide.
In plain wordsIn IVF/ICSI patients, estradiol was lower with cetrorelix 0.2 mg than depot leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseEstradiol
Study
n: not reported in source
Comparator
Leuprolide acetate depot 1.88 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Estradiol
1010.8 pg/mL
cetrorelix 0.2 mg
Estradiol
1313.5 pg/mL
single half-dose leuprolide acetate depot 1.88 mg
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058543
44HumanNon-randomized trialEfficacy outcome
In IVF/ICSI patients, estradiol was lower with cetrorelix 0.15 mg: 1,023.6 versus 1,313.5 pg/mL with depot leuprolide.
In plain wordsIn IVF/ICSI patients, estradiol was lower with cetrorelix 0.15 mg than depot leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseEstradiol
Study
n: not reported in source
Comparator
Leuprolide acetate depot 1.88 mg
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
Estradiol
1023.6 pg/mL
cetrorelix 0.15 mg
Estradiol
1313.5 pg/mL
single half-dose leuprolide acetate depot 1.88 mg
Source sentences
Summary
Gn dosages (IU)/E2 levels (pg/mL) in each group were: (1) 1,949.4/1,191.1; (2) 1,869.6/1,010.8; (3) 1,856.7/1,023.6; (4) 2,184.5/1,323.6; and (5) 2,103.5/1,313.5, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058544
45HumanNon-randomized trialSafety outcome
In IVF/ICSI patients, OHSS risk was lower with cetrorelix 0.25 mg: 5.8% versus 8.2% with depot leuprolide.
In plain wordsIn IVF/ICSI patients, ovarian hyperstimulation syndrome (OHSS) risk was lower with cetrorelix 0.25 mg than with depot leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseOHSS risk
Study
n: not reported in source
Comparator
Leuprolide acetate depot 1.88 mg
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.25 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
OHSS risk
5.8%
cetrorelix 0.25 mg
OHSS risk
8.2%
single half-dose leuprolide acetate depot 1.88 mg
Source sentences
Summary
LH/OHSS risks were: (1) 3.5%/5.8%; (2) 7.1%/3.6%; (3) 13.3%/3.3%; (4) 3.4%/8.6%; and (5) 2%/8.2%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058545
46HumanNon-randomized trialSafety outcome
In IVF/ICSI patients, OHSS risk was lower with cetrorelix 0.2 mg: 3.6% versus 8.2% with depot leuprolide.
In plain wordsIn IVF/ICSI patients, ovarian hyperstimulation syndrome (OHSS) risk was lower with cetrorelix 0.2 mg than with depot leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseOHSS risk
Study
n: not reported in source
Comparator
Leuprolide acetate depot 1.88 mg
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.2 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
OHSS risk
3.6%
cetrorelix 0.2 mg
OHSS risk
8.2%
single half-dose leuprolide acetate depot 1.88 mg
Source sentences
Summary
LH/OHSS risks were: (1) 3.5%/5.8%; (2) 7.1%/3.6%; (3) 13.3%/3.3%; (4) 3.4%/8.6%; and (5) 2%/8.2%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058546
47HumanNon-randomized trialSafety outcome
In IVF/ICSI patients, OHSS risk was lower with cetrorelix 0.15 mg: 3.3% versus 8.2% with depot leuprolide.
In plain wordsIn IVF/ICSI patients, ovarian hyperstimulation syndrome (OHSS) risk was lower with cetrorelix 0.15 mg than with depot leuprolide.
Peptide
Cetrorelix
Outcome
DecreaseOHSS risk
Study
n: not reported in source
Comparator
Leuprolide acetate depot 1.88 mg
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
0.15 mg daily · From menstrual day 8 until hCG administrationAs given in this study (human).
Measurements
OHSS risk
3.3%
cetrorelix 0.15 mg
OHSS risk
8.2%
single half-dose leuprolide acetate depot 1.88 mg
Source sentences
Summary
LH/OHSS risks were: (1) 3.5%/5.8%; (2) 7.1%/3.6%; (3) 13.3%/3.3%; (4) 3.4%/8.6%; and (5) 2%/8.2%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
We observed lower gonadotropin (Gn) dosages, estradiol (E2) levels and reduced risk of ovarian hyperstimulation syndrome (OHSS) in the GnRH antagonist groups.
Summary · context
Women undergoing in vitro fertilization/intracytoplasmic sperm injection and embryo transfer were divided into five groups: (1) cetrorelix 0.25 mg ( n = 86); (2) cetrorelix 0.2 mg ( n = 28); (3) cetrorelix 0.15 mg ( n = 30); (4) leuprolide acetate (LA) 0.5 mg/day ( n = 58); (5) single half-dose LA d…
Summary · context
Cetrorelix was administered daily from menstrual day 8 until the day of human chorionic gonadotropin administration.
Report a problemFND-1840058547

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.